<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02350478</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2012-01</org_study_id>
    <nct_id>NCT02350478</nct_id>
  </id_info>
  <brief_title>Effects of Linagliptin on Endothelial Function</brief_title>
  <official_title>Effects of Linagliptin on Endothelial Function and Global Arginine Bioavailability Ratio in Coronary Artery Disease Patients With Early Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned to evaluate if linagliptin can improve endothelial function in patients
      with type 2 diabetes mellitus. In addition, the effect of linagliptin on arginine
      bioavailability ratios and postchallenge glycaemic control will be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type 2 diabetes (T2DM) are at increased risk of macrovascular events as well as
      microvascular complications. It is well known, that the pathophysiologic process of type 2
      diabetes starts many years before the diagnosis can be made on the basis of elevated fasting
      blood glucose. In particular the data of the United Kingdom Prospective Diabetes Study
      (UKPDS) study and the UKPDS post trial monitoring highlighted the importance of an early
      glucose lowering intervention in patients with T2DM with respect to micro- and macrovascular
      complications. The investigators and in particular the Euro Heart survey on Diabetes and the
      Heart demonstrated, that in a cardiovascular high risk population, namely patients with
      coronary artery disease (CAD), about 35% suffer from manifest type 2 diabetes. In addition,
      another 9 to 15% of CAD patients have postchallenge diabetes, diagnosed on the basis of an
      oral glucose tolerance test, which means that approximately a half of all patients with CAD
      have diabetes.

      Recently the investigators could demonstrate that not only established type 2 diabetes
      diagnosed on the basis of fasting hyperglycaemia is associated with an increased
      cardiovascular risk, but also postchallenge hyperglycemia (i.e. impaired glucose tolerance or
      postchallenge diabetes).

      Dipeptidylpeptidase-4 (DPP-4) inhibitors increase endogenous glucagon like-peptide-1 (GLP-1)
      levels and GLP-1 in turn increases the insulin release from pancreatic beta-cells in a
      glucose dependent manner as well as suppresses glucagon secretion from pancreatic alpha
      cells. Investigations in type 2 diabetic patients showed that this drug class lowers both,
      fasting and postchallenge or postmeal glucose levels and hence, HbA1c and is well tolerated.

      However, the lowering of the surrogate measurement HbA1c has not necessarily turned out to
      translate into a reduced number of cardiovascular events in patients with T2DM. In contrary
      in particular for the thiazolidinedione Rosiglitazone concerns about an increased risk of
      cardiovascular events have been raised despite a robust HbA1c lowering effect.Therefore the
      Food and Drug Administration (FDA) and the European Medicines Agency (EMA) issued in 2008 and
      2010, respectively, guidance for new glucose lowering drugs, requiring proof of at least
      cardiovascular safety. Cardiovascular outcome trials with Linagliptin are currently being
      performed (CAROLINA, CARMELINA), however, it will take a couple of years until the results
      are available.A well known and validated cardiovascular surrogate parameter is endothelial
      dysfunction. The investigators and others have shown previously, that endothelial dysfunction
      is present in patients with coronary artery disease and early diabetes and can be improved by
      pharmacological intervention. This surrogate measurement could be helpful in better
      understanding the cardiovascular effects of Linagliptin while awaiting the results of the
      definitive outcome trials.

      The aim of this study is to investigate the effects of Linagliptin in coronary patients with
      early T2DM on various cardiovascular surrogate measurements including mechanical and
      biochemical endothelial function assessments. The overarching aim of our study is to
      investigate the effects of Linagliptin on endothelial function, arginine bioavailability
      ratios and postchallenge glycaemic control in patients with early diabetes and coronary
      atherosclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Endothelial Function (FMD - Flow Mediated Dilatation) From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Endothelium-dependent FMD following reactive hyperaemia was examined in the brachial artery according to the guidelines described by Coretti et al (J Am Coll Cardiol. 2002;39(2):257-65). FMD-diameter is calculated as the average of the three diameter measurements following reactive hyperaemia. FMD was calculated as the percent change in diameter compared to baseline. Flow-mediated dilation is reported such as &quot;percentage of change in diameter (%)&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Global Arginine Bioavailability Ratio (Ratio of Arginine to [Ornithine + Citrulline]) and Arginine to Ornithine Ratio From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Arginine, ornithine and citrulline will be measured in serum samples with a conventional usual amino acid analysis technique, involving separation of amino acids by ion exchange chromatography followed by postcolumn continuous reaction with ninhydrin. Global arginine bioavailability ratio (GABR) will be calculated by L-arginine divided by the sum of (L-ornithine plus L-citrulline). The arginine to ornithine ratio will be calculated by dividing L-arginine by L-ornithine levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Biochemical Markers (sICAM-1)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Soluble cell adhesion molecules-1 (sICAM-1) of endothelial function from baseline to 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Area Under Curve (AUC) of Glucose, Insulin and C-peptide During the Meal Tolerance Test From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Area under the curve was calculated for glucose, insulin and for the free fatty acids based on the trapezoidal rule with baseline value as the mean of the values at time points -5 and 0 minutes.
The Meal Tolerance Test (MTT) was performed after an overnight fast (apart from water). A pre-meal blood sample will be taken (-5mins) and then all subjects will be asked to drink Fortimel compact (10 kcal/kg) over a period of 2-4 mins (time 0 mins). During the mixed meal test further blood samples will be taken at 15, 30, 60, and 120 minutes. All samples will be used for the determination of glucose, insulin and free fatty acids. The blood at each time point will be placed into a fluoride oxalate tube (1ml) for plasma glucose and into a serum tube for insulin and free fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Area Under Curve (AUC) of Free Fatty Acids During the Meal Tolerance Test From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Area under the curve was calculated for glucose, insulin and for the free fatty acids based on the trapezoidal rule with baseline value as the mean of the values at time points -5 and 0 minutes.
The MTT was performed after an overnight fast (apart from water). A pre-meal blood sample will be taken (-5mins) and then all subjects will be asked to drink Fortimel compact (10 kcal/kg) over a period of 2-4 mins (time 0 mins). During the mixed meal test further blood samples will be taken at 15, 30, 60, and 120 minutes. All samples will be used for the determination of glucose, insulin and free fatty acids. The blood at each time point will be placed into a fluoride oxalate tube (1ml) for plasma glucose and into a serum tube for insulin and free fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Biochemical Markers (svCAM-1)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Soluble cell adhesion molecules-1 (svCAM-1) of endothelial function from baseline to 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
    <arm_group_label>Linagliptin</arm_group_label>
    <other_name>Trajenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The subject will receive placebo orally once daily for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 40 to 80 years

          -  Early diabetes (postchallenge diabetes (2h glucose &gt;200 mg/dl or type 2 diabetes
             treated with diet only or on a stable dose of metformin monotherapy)

          -  Coronary atherosclerosis (diagnosed via coronary angiography or coronary computer
             tomography)

        Exclusion Criteria:

          -  Acute coronary syndrome or cerebrovascular event within the previous 4 weeks

          -  Body Mass Index (BMI) &gt; 35 kg/m2

          -  HbA1c &lt;6.0% (42 mmol/mol)

          -  Serum creatinine &gt; 2.5 mg/dl

          -  Aspartate Transaminase (AST)/Alanine Transaminase (ALT)&gt;3x upper limit of normal

          -  HbA1c &gt;9.0% (&gt;75 mmol/mol)

          -  Heart failure &gt; New York Heart Association (NYHA) class II

          -  Uncontrolled hypertension (blood pressure &gt; 165 / 100 mmHg)

          -  Treatment with orally administered steroids

          -  New onset statin or Angiotensin Converting Enzym- (ACE-) inhibitor within the previous
             6 weeks

          -  Known Malignancy

          -  Pregnancy or breast feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Sourij, Assoc.-Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz, Department for Internal Medicine</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <results_first_submitted>February 19, 2019</results_first_submitted>
  <results_first_submitted_qc>December 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2019</results_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 24, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02350478/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Linagliptin</title>
          <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
Linagliptin: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>The subjects will receive placebo.
Placebo: The subject will receive placebo orally once daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Linagliptin</title>
          <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
Linagliptin: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>The subjects will receive placebo.
Placebo: The subject will receive placebo orally once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="7.8"/>
                    <measurement group_id="B2" value="63.3" spread="8.7"/>
                    <measurement group_id="B3" value="63.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure systolic (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134" spread="17"/>
                    <measurement group_id="B2" value="128" spread="18"/>
                    <measurement group_id="B3" value="131" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure diastolic (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79" spread="14"/>
                    <measurement group_id="B2" value="78" spread="10"/>
                    <measurement group_id="B3" value="79" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low density lipoprotein (mg/dl)</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="31"/>
                    <measurement group_id="B2" value="76" spread="43"/>
                    <measurement group_id="B3" value="71" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides (mg/dl)</title>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145" lower_limit="54" upper_limit="480"/>
                    <measurement group_id="B2" value="122" lower_limit="63" upper_limit="255"/>
                    <measurement group_id="B3" value="128" lower_limit="90" upper_limit="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c (mmol/mol)</title>
          <units>mmol/mol</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" lower_limit="43" upper_limit="69"/>
                    <measurement group_id="B2" value="51" lower_limit="39" upper_limit="78"/>
                    <measurement group_id="B3" value="51" lower_limit="45.5" upper_limit="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting blood glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136" spread="41"/>
                    <measurement group_id="B2" value="123" spread="26"/>
                    <measurement group_id="B3" value="135" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate-Aminotransferase (U/L)</title>
          <units>U/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="14"/>
                    <measurement group_id="B2" value="27.6" spread="8.3"/>
                    <measurement group_id="B3" value="30.4" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine-Aminotransferase (U/L)</title>
          <units>U/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="25"/>
                    <measurement group_id="B2" value="29" spread="12.7"/>
                    <measurement group_id="B3" value="34.4" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine (mg/dL)</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.3"/>
                    <measurement group_id="B2" value="1.0" spread="0.2"/>
                    <measurement group_id="B3" value="1.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>estimated glomerular filtration rate (ml/min)</title>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.7" spread="16.1"/>
                    <measurement group_id="B2" value="80.8" spread="18.0"/>
                    <measurement group_id="B3" value="78.9" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>c-reactive protein (mg/L)</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="4.2"/>
                    <measurement group_id="B2" value="7.6" spread="20.4"/>
                    <measurement group_id="B3" value="5.8" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine albumine´(mg/L)</title>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="68.1"/>
                    <measurement group_id="B2" value="30.3" spread="43.4"/>
                    <measurement group_id="B3" value="40.8" spread="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>n-terminal-proBNP (pg/ml)</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="419" spread="528"/>
                    <measurement group_id="B2" value="228" spread="452"/>
                    <measurement group_id="B3" value="317" spread="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Endothelial Function (FMD - Flow Mediated Dilatation) From Baseline to 12 Weeks</title>
        <description>Endothelium-dependent FMD following reactive hyperaemia was examined in the brachial artery according to the guidelines described by Coretti et al (J Am Coll Cardiol. 2002;39(2):257-65). FMD-diameter is calculated as the average of the three diameter measurements following reactive hyperaemia. FMD was calculated as the percent change in diameter compared to baseline. Flow-mediated dilation is reported such as &quot;percentage of change in diameter (%)&quot;.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
Linagliptin: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The subjects will receive placebo.
Placebo: The subject will receive placebo orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Endothelial Function (FMD - Flow Mediated Dilatation) From Baseline to 12 Weeks</title>
          <description>Endothelium-dependent FMD following reactive hyperaemia was examined in the brachial artery according to the guidelines described by Coretti et al (J Am Coll Cardiol. 2002;39(2):257-65). FMD-diameter is calculated as the average of the three diameter measurements following reactive hyperaemia. FMD was calculated as the percent change in diameter compared to baseline. Flow-mediated dilation is reported such as &quot;percentage of change in diameter (%)&quot;.</description>
          <units>percentage of change in diameter (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="4.8"/>
                    <measurement group_id="O2" value="-0.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Global Arginine Bioavailability Ratio (Ratio of Arginine to [Ornithine + Citrulline]) and Arginine to Ornithine Ratio From Baseline to 12 Weeks</title>
        <description>Arginine, ornithine and citrulline will be measured in serum samples with a conventional usual amino acid analysis technique, involving separation of amino acids by ion exchange chromatography followed by postcolumn continuous reaction with ninhydrin. Global arginine bioavailability ratio (GABR) will be calculated by L-arginine divided by the sum of (L-ornithine plus L-citrulline). The arginine to ornithine ratio will be calculated by dividing L-arginine by L-ornithine levels.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
Linagliptin: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The subjects will receive placebo.
Placebo: The subject will receive placebo orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Global Arginine Bioavailability Ratio (Ratio of Arginine to [Ornithine + Citrulline]) and Arginine to Ornithine Ratio From Baseline to 12 Weeks</title>
          <description>Arginine, ornithine and citrulline will be measured in serum samples with a conventional usual amino acid analysis technique, involving separation of amino acids by ion exchange chromatography followed by postcolumn continuous reaction with ninhydrin. Global arginine bioavailability ratio (GABR) will be calculated by L-arginine divided by the sum of (L-ornithine plus L-citrulline). The arginine to ornithine ratio will be calculated by dividing L-arginine by L-ornithine levels.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Arginine Bioavailabilty Ratio (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.35"/>
                    <measurement group_id="O2" value="-0.06" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arginine to ornithine ratio (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.45"/>
                    <measurement group_id="O2" value="-0.05" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Biochemical Markers (sICAM-1)</title>
        <description>Soluble cell adhesion molecules-1 (sICAM-1) of endothelial function from baseline to 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
Linagliptin: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The subjects will receive placebo.
Placebo: The subject will receive placebo orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Biochemical Markers (sICAM-1)</title>
          <description>Soluble cell adhesion molecules-1 (sICAM-1) of endothelial function from baseline to 12 weeks</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15" lower_limit="-272" upper_limit="103"/>
                    <measurement group_id="O2" value="-21" lower_limit="-134" upper_limit="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Area Under Curve (AUC) of Glucose, Insulin and C-peptide During the Meal Tolerance Test From Baseline to 12 Weeks</title>
        <description>The Area under the curve was calculated for glucose, insulin and for the free fatty acids based on the trapezoidal rule with baseline value as the mean of the values at time points -5 and 0 minutes.
The Meal Tolerance Test (MTT) was performed after an overnight fast (apart from water). A pre-meal blood sample will be taken (-5mins) and then all subjects will be asked to drink Fortimel compact (10 kcal/kg) over a period of 2-4 mins (time 0 mins). During the mixed meal test further blood samples will be taken at 15, 30, 60, and 120 minutes. All samples will be used for the determination of glucose, insulin and free fatty acids. The blood at each time point will be placed into a fluoride oxalate tube (1ml) for plasma glucose and into a serum tube for insulin and free fatty acids.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
Linagliptin: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The subjects will receive placebo.
Placebo: The subject will receive placebo orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Area Under Curve (AUC) of Glucose, Insulin and C-peptide During the Meal Tolerance Test From Baseline to 12 Weeks</title>
          <description>The Area under the curve was calculated for glucose, insulin and for the free fatty acids based on the trapezoidal rule with baseline value as the mean of the values at time points -5 and 0 minutes.
The Meal Tolerance Test (MTT) was performed after an overnight fast (apart from water). A pre-meal blood sample will be taken (-5mins) and then all subjects will be asked to drink Fortimel compact (10 kcal/kg) over a period of 2-4 mins (time 0 mins). During the mixed meal test further blood samples will be taken at 15, 30, 60, and 120 minutes. All samples will be used for the determination of glucose, insulin and free fatty acids. The blood at each time point will be placed into a fluoride oxalate tube (1ml) for plasma glucose and into a serum tube for insulin and free fatty acids.</description>
          <units>mg*min/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1135" spread="2619"/>
                    <measurement group_id="O2" value="481" spread="3185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-peptide AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="161"/>
                    <measurement group_id="O2" value="-34" spread="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249" spread="4766"/>
                    <measurement group_id="O2" value="40" spread="6357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Area Under Curve (AUC) of Free Fatty Acids During the Meal Tolerance Test From Baseline to 12 Weeks</title>
        <description>The Area under the curve was calculated for glucose, insulin and for the free fatty acids based on the trapezoidal rule with baseline value as the mean of the values at time points -5 and 0 minutes.
The MTT was performed after an overnight fast (apart from water). A pre-meal blood sample will be taken (-5mins) and then all subjects will be asked to drink Fortimel compact (10 kcal/kg) over a period of 2-4 mins (time 0 mins). During the mixed meal test further blood samples will be taken at 15, 30, 60, and 120 minutes. All samples will be used for the determination of glucose, insulin and free fatty acids. The blood at each time point will be placed into a fluoride oxalate tube (1ml) for plasma glucose and into a serum tube for insulin and free fatty acids.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
Linagliptin: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The subjects will receive placebo.
Placebo: The subject will receive placebo orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Area Under Curve (AUC) of Free Fatty Acids During the Meal Tolerance Test From Baseline to 12 Weeks</title>
          <description>The Area under the curve was calculated for glucose, insulin and for the free fatty acids based on the trapezoidal rule with baseline value as the mean of the values at time points -5 and 0 minutes.
The MTT was performed after an overnight fast (apart from water). A pre-meal blood sample will be taken (-5mins) and then all subjects will be asked to drink Fortimel compact (10 kcal/kg) over a period of 2-4 mins (time 0 mins). During the mixed meal test further blood samples will be taken at 15, 30, 60, and 120 minutes. All samples will be used for the determination of glucose, insulin and free fatty acids. The blood at each time point will be placed into a fluoride oxalate tube (1ml) for plasma glucose and into a serum tube for insulin and free fatty acids.</description>
          <units>µmol*min/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="28.4"/>
                    <measurement group_id="O2" value="-3.1" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Biochemical Markers (svCAM-1)</title>
        <description>Soluble cell adhesion molecules-1 (svCAM-1) of endothelial function from baseline to 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
Linagliptin: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The subjects will receive placebo.
Placebo: The subject will receive placebo orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Biochemical Markers (svCAM-1)</title>
          <description>Soluble cell adhesion molecules-1 (svCAM-1) of endothelial function from baseline to 12 weeks</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34" spread="84"/>
                    <measurement group_id="O2" value="5" spread="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 16 weeks (12 weeks of intervention and 4 weeks of follow-up).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Linagliptin</title>
          <description>The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
Linagliptin: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>The subjects will receive placebo.
Placebo: The subject will receive placebo orally once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Hospitalisation due to abdominal pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Borreliosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>discus prolaps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coordinating disorders</sub_title>
                <description>Hospitalization due to coordinating disorders</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dorsal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Claudicatio intermittens</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Assoz.-Prof. Dr. Harald Sourij</name_or_title>
      <organization>Medical University of Graz</organization>
      <phone>+43316385 ext 81310</phone>
      <email>ha.sourij@medunigraz.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

